|
Pharmaceuticals Sector
En route for tomorrow’s Solvay Pharmaceuticals
Sales: EUR 2.6 billion – REBIT*: EUR 457 million
9 178 employees
Therapeutic fields
Integrated franchises (R&D and commercial)
- Cardiometabolics (dyslipidemia, obesity, type 2 diabetes, congestive heart failure, renal insufficiency, atrial fibrillation);
- Neuroscience (schizophrenia, Parkinson’s disease, traumatic brain injury, cognition);
- Niches in flu vaccines and pancreatic enzymes.
Commercial franchises
- Gastroenterology;
- Women’s and men’s health.
Strategic priorities (2010)
- Concentration on therapeutic fields;
- Improving profitability:
Operating margin**: 20%;
Efficiency improvements:
EUR 300 million of annual savings;
- Sales: EUR 3.2 billion;
- Increasing the R&D/sales ratio.
Chemicals Sector
On the path of growth
Sales: EUR 3.0 billion – REBIT*: EUR 345 million
8 395 employees
4 clusters
Minerals
- Soda ash and derivatives (bicarbonate);
- Advanced Functional Minerals (precipitated calcium carbonate).
Electrochemistry, fluorinated products
- Electrochemicals and derivatives (caustic soda, epichlorohydrin);
- Fluorinated products.
Oxygen
- Hydrogen peroxide;
- Detergents (persalts).
Organic (Molecular Solutions)
Strategic priorities
- Intensifying our geographic expansion;
- Pursuing technological innovation;
- Growth in specialties (mainly bicarbonate and fluorinated and organic specialties);
- Competitiveness.
Plastics Sector
Enriching our product portfolio and fully exploiting our strengths
Sales: EUR 4.0 billion – REBIT*: EUR 441 million
8 977 employees
2 clusters
Specialties
- Specialty Polymers (high and ultra-high performance polymers like fluorinated polymers, elastomers and fluids, barrier materials, polyarylamides, polysulfones, high performance polyamides, liquid crystal polymers);
- Inergy Automotive Systems (50/50 joint venture with Plastic Omnium).
Vinylics
- Vinyls (integrated electrolysis chain, VCM (monomer), PVC (polymer) and PVC compounds);
- Pipelife (50/50 joint venture with Wienerberger).
Strategic priorities
- Globalization;
- R&D and technological innovation;
- Product leadership;
- Competitiveness.
* REBIT= "Recurring Earnings Before Interests and Taxes" = operating results
** REBIT/sales
|
